Drugs / BOXR1030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05120271 | Oct 2022 → Oct 2025 overdue | cutaneous neuroendocrine carcinoma, hepatocellular carcinoma, myxoid/round cell liposarcoma, squamous cell lung carcinoma | SOTIO Biotech AG | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOXR1030 | “One time intravenous administration of BOXR1030 after completion of cyclophosphamide and fludarabine LD chemotherapy” NCT05120271 ↗ |
| Modality | Cell therapy | “We developed and evaluated BOXR1030, a novel CAR T therapeutic co-expressing glypican-3 (GPC3)-targeted CAR and exogenous glutamic-oxaloacetic transaminase 2 (GOT2)” PMID 35507536 ↗ May 2022 |
| Route | Intravenous | “One time intravenous administration of BOXR1030 after completion of cyclophosphamide and fludarabine LD chemotherapy” NCT05120271 ↗ |
| Target | GPC3 | “glypican-3 (GPC3)-targeted CAR” PMID 35507536 ↗ May 2022 |